Interview with Olivier Daubry, General Manager, Celgene France
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
Address: 16/18, Rue du Quatre Septembre
75002 Paris
,France
Tel: +33 1 53 42 43 00
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.
Celgene seeks to deliver truly innovative and life-changing drugs for our patients. It’s mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
Thanks to the establishment of its structure in France, a 100% subsidiary of Celgene Corporation, Celgene France ensures its presence on the French health market. Celgene France, besides the marketing of drugs, will establish many clinical trials of new molecules derived from the R&D of Celgene. These, of course, will be conducted in cooperation with the most recognized French medical institutions.
There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin’s lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.
Global Products
ISTODAX® (romidepsin) for injection
REVLIMID® (lenalidomide)
THALOMID® (thalidomide)
VIDAZA® (azacitidine for injection)
Services
LifebankUSA (placental and cord blood banking)
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
France Alzheimer’s Joel Jaouen and Benoit Durand articulate a comprehensive strategic framework for addressing one of Europe’s most pressing healthcare challenges. With four decades of operational excellence, the organisation has…
With only a handful of patients affected by each condition, rare diseases present a unique set of scientific, medical, and economic challenges. At the heart of this complex landscape is…
Alexis Genin, CEO of Brain & Mind, discusses the strategic vision behind France’s first national hub for neuroscience product development. Established to overcome the fragmented landscape in neuroscience innovation, Brain…
Europe has a plasma problem. The continent is over-reliant on the US for plasma – donated, purified human blood liquid – which is a key component in several lifesaving drugs…
Professor Jean-Yves Blay stands as a distinguished figure in contemporary oncology, serving simultaneously as a practising medical oncologist, cancer researcher, and institutional leader. Currently director general of a comprehensive cancer…
Virginie Beaumeunier, head of France’s CEPS, brings deep expertise in competition law and economic regulation to pharmaceutical pricing. Her background—including roles at the Finance Inspectorate and Competition Authority—shapes her approach…
Professor Alain Puisieux, President of the Executive Board at Institut Curie, leads the renowned cancer centre through an integrated strategy combining cutting-edge research and patient care. With a scientific background…
Founded in 2017 as part of France’s national health export strategy, the French Healthcare Association brings together more than 300 members from across the health ecosystem to showcase and support…
Seven years after our last discussion, GREENTECH has expanded its international presence, reinforced its leadership in dermocosmetics, and deepened its role in pharmaceuticals. In this interview, CEO Jean-Yves Berthon reflects…
Fabien Riolet leads Polepharma, France’s leading pharmaceutical manufacturing network, driving industrial sovereignty and innovation across 460 member companies. Under his leadership, it has evolved into a strategic hub for manufacturing…
With demand for plasma-derived therapies rising steadily and Europe rethinking its biomanufacturing sovereignty, France’s LFB is quietly positioning itself for a leap onto the global stage. Backed by a EUR…
Etienne Tichit has dedicated over five years to steering Novo Nordisk France through a transformative period of unprecedented growth and strategic realignment. His tenure has been marked by bold industrial…
See our Cookie Privacy Policy Here
